TY - JOUR
T1 - The nationwide study of bacterial pathogens associated with urinary tract infections conducted by the Japanese Society of Chemotherapy
AU - Ishikawa, Kiyohito
AU - Matsumoto, Tetsuro
AU - Yasuda, Mitsuru
AU - Uehara, Shinya
AU - Muratani, Tetsuro
AU - Yagisawa, Morimasa
AU - Sato, Junko
AU - Niki, Yoshihito
AU - Totsuka, Kyoichi
AU - Sunakawa, Keisuke
AU - Hanaki, Hideaki
AU - Hattori, Rikizo
AU - Terada, Michinori
AU - Kozuki, Tsuneo
AU - Maruo, Akinori
AU - Morita, Kohei
AU - Ogasawara, Kazuhiko
AU - Takahashi, Yoshisaburo
AU - Matsuda, Kenji
AU - Hirose, Takaoki
AU - Miyao, Noriomi
AU - Hayashi, Tasuku
AU - Takeyama, Koh
AU - Kiyota, Hiroshi
AU - Tomita, Masayuki
AU - Yusu, Hisashi
AU - Koide, Haruhisa
AU - Kimura, Shoji
AU - Yanaoka, Masanori
AU - Sato, Hajime
AU - Ito, Toru
AU - Deguchi, Takashi
AU - Fujimoto, Yoshinori
AU - Komeda, Hisao
AU - Asano, Yuko
AU - Takahashi, Yoshito
AU - Ishihara, Satoshi
AU - Arakawa, Soichi
AU - Nakano, Yuzo
AU - Tanaka, Kazushi
AU - Fujisawa, Masato
AU - Matsui, Takashi
AU - Fujii, Akira
AU - Yamamoto, Shingo
AU - Nojima, Michio
AU - Higuchi, Yoshihide
AU - Ueda, Yasuo
AU - Kanamaru, Sojun
AU - Monden, Koichi
AU - Tsushima, Tomoyasu
AU - Seno, Yuko
AU - Tsugawa, Masaya
AU - Takenaka, Tadasu
AU - Hamasuna, Ryoichi
AU - Fujimoto, Naohiro
AU - Sho, Takehiko
AU - Takahashi, Koichi
AU - Inatomi, Hisato
AU - Takahashi, Naoya
AU - Ikei, Yoshihiko
AU - Hayami, Hiroshi
AU - Yamane, Takashi
AU - Nakagawa, Masayuki
AU - Kariya, Satoru
AU - Arima, Takashi
N1 - Funding Information:
Acknowledgments This study was supported by grants from the following pharmaceutical companies (listed in alphabetical order): Abbott Japan Co., Ltd.; Astellas Pharma Inc.; Banyu Pharmaceutical Co., Ltd.; Bayer Yakuhin, Ltd.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Dainippon Sumitomo Pharma Co., Ltd.; GlaxoSmithKline K. K.; Kyorin Pharmaceutical Co., Ltd.; Maruho Co., Ltd.; Meiji Seika Kaisha, Ltd.; Pfizer Japan Inc.; Sanofi-Aventis K.K.; Shionogi & Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Taisho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; and Toyama Chemical Co., Ltd. We are grateful to T. Nakae and C. Yanagisawa of Kitasato University (Tokyo, Japan) for their encouragement, and we thank Y. Suzuki, H. Endo, and Y. Yamaguchi for their technical assistance.
PY - 2011/2
Y1 - 2011/2
N2 - This study was conducted by the Japanese Society of Chemotherapy and is the first nationwide study on bacterial pathogens isolated from patients with urinary tract infections at 28 hospitals throughout Japan between January 2008 and June 2008. A total of 688 bacterial strains were isolated from adult patients with urinary tract infections. The strains investigated in this study are as follows: Enterococcus faecalis (n = 140), Escherichia coli (n = 255), Klebsiella pneumoniae (n = 93), Proteus mirabilis (n = 42), Serratia marcescens (n = 44), and Pseudomonas aeruginosa (n = 114). The minimum inhibitory concentrations of 39 antibacterial agents used for these strains were determined according to the Clinical and Laboratory Standards Institute (CLSI) manual. All Enterococcus faecalis strains were susceptible to ampicillin and vancomycin. Although a majority of the E. faecalis strains were susceptible to linezolid, 11 strains (7.8%) were found to be intermediately resistant. The proportions of fluoroquinolone-resistant Enterococcus faecalis, Escherichia coli, Proteus mirabilis, and S. marcescens strains were 35.7%, 29.3%, 18.3%, and 15.2%, respectively. The proportions of E. coli, P. mirabilis, K. pneumoniae, and S. marcescens strains producing extended-spectrum β-lactamase were 5.1%, 11.9%, 0%, and 0%, respectively. The proportions of Pseudomonas aeruginosa strains resistant to carbapenems, aminoglycosides, and fluoroquinolones were 9.2%, 4.4%, and 34.8%, respectively, and among them, 2 strains (1.8%) were found to be multidrug resistant. These data present important information for the proper treatment of urinary tract infections and will serve as a useful reference for periodic surveillance studies in the future.
AB - This study was conducted by the Japanese Society of Chemotherapy and is the first nationwide study on bacterial pathogens isolated from patients with urinary tract infections at 28 hospitals throughout Japan between January 2008 and June 2008. A total of 688 bacterial strains were isolated from adult patients with urinary tract infections. The strains investigated in this study are as follows: Enterococcus faecalis (n = 140), Escherichia coli (n = 255), Klebsiella pneumoniae (n = 93), Proteus mirabilis (n = 42), Serratia marcescens (n = 44), and Pseudomonas aeruginosa (n = 114). The minimum inhibitory concentrations of 39 antibacterial agents used for these strains were determined according to the Clinical and Laboratory Standards Institute (CLSI) manual. All Enterococcus faecalis strains were susceptible to ampicillin and vancomycin. Although a majority of the E. faecalis strains were susceptible to linezolid, 11 strains (7.8%) were found to be intermediately resistant. The proportions of fluoroquinolone-resistant Enterococcus faecalis, Escherichia coli, Proteus mirabilis, and S. marcescens strains were 35.7%, 29.3%, 18.3%, and 15.2%, respectively. The proportions of E. coli, P. mirabilis, K. pneumoniae, and S. marcescens strains producing extended-spectrum β-lactamase were 5.1%, 11.9%, 0%, and 0%, respectively. The proportions of Pseudomonas aeruginosa strains resistant to carbapenems, aminoglycosides, and fluoroquinolones were 9.2%, 4.4%, and 34.8%, respectively, and among them, 2 strains (1.8%) were found to be multidrug resistant. These data present important information for the proper treatment of urinary tract infections and will serve as a useful reference for periodic surveillance studies in the future.
UR - http://www.scopus.com/inward/record.url?scp=79951551846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951551846&partnerID=8YFLogxK
U2 - 10.1007/s10156-010-0174-1
DO - 10.1007/s10156-010-0174-1
M3 - Article
C2 - 21174142
AN - SCOPUS:79951551846
SN - 1341-321X
VL - 17
SP - 126
EP - 138
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 1
ER -